sar425899 glucagon glp-1 dual agonist sanofi Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy | Diabetologia Focus on Glucagon-like Peptide-1 Target:

Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials

The new class of weight-loss medications are hailed as game-changing wonder drugs, but just how safe and effective are they

Gastrointestinal issues such as nausea, vomiting, diarrhea, and abdominal pain are among the most frequently reported side effects, especially at the start of treatment

In a recent Managed Healthcare Executive pharmacy survey, plan sponsors, []

SAN DIEGO(March 10, 2025)Glucagon-like peptide-1 receptor agonists (GLP-1 agonists), such as semaglutide (e.g., Ozempic), have helped improve the management of type 2 diabetes and obesity

It's more effective than semaglutide (a single GLP-1 agonist) for weight loss and blood sugar control